Income statement
EUR
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 945M | 993M | 1.0B | 1.1B | 970M |
| Gross Profit | 576M | 593M | 602M | 597M | 446M |
| Operating Income | 62M | 39M | 8M | 48M | 26M |
| EBITDA | 98M | 82M | 48M | 81M | 69M |
| Net Income | 47M | 22M | -25M | 54M | 21M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$3.76
+0.00% today
1Y Change
+68.61%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 255 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Safilo Group S.p.A. (SAFLY) is a Healthcare stock with a market cap of $600.00M and listed on OTC. The stock last traded around $3.76 and up 68.6% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of -4.9%, EPS growth of +308.9%, a dividend yield of 0.0%. What stands out right now is revenue -4.9%, EPS +308.9%, free cash flow +183.8% with operating margin 5.1% and ROIC 6.7%. Valuation is more restrained than many high-expectation growth names at P/E 14.1 and price/sales 0.6. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SAFLY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SAFLY
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SAFLY Max Drawdown
-14.16%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SAFLY and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$969.6M
-10.0% YoY
FY Net Income
$21.3M
-60.7% YoY
Free Cash Flow
-$2.7M
+60.4% YoY
Revenue Growth
-4.9%
EPS Growth
+308.9%
Gross Margin
60.9%
Net Margin
5.0%
Income statement
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 945M | 993M | 1.0B | 1.1B | 970M |
| Gross Profit | 576M | 593M | 602M | 597M | 446M |
| Operating Income | 62M | 39M | 8M | 48M | 26M |
| EBITDA | 98M | 82M | 48M | 81M | 69M |
| Net Income | 47M | 22M | -25M | 54M | 21M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 52M | 47M | 75M | 78M | 99M |
| Total Assets | 759M | 842M | 855M | 960M | 938M |
| Total Liabilities | 356M | 415M | 460M | 521M | 572M |
| Shareholder Equity | 392M | 413M | 379M | 410M | 327M |
| Total Debt | 98M | 130M | 158M | 191M | 193M |
| Net Debt | 46M | 83M | 83M | 113M | 94M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
17M
+88.9% YoY
Capital Expenditures
20M
-25.8% YoY
Free Cash Flow
3M
+60.4% YoY
Key ratios
Gross Margin
60.9%
Operating Margin
5.1%
Net Margin
5.0%
ROE
12.4%
Debt / Equity
0.25x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.